1020P - Clinical impact of atypical phenotypes in adult t cell lymphoma/leukemia among HTLV carriers

Date 09 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancers in Adolescents and Young Adults (AYA)
Haematologic Malignancies
Presenter Daniel Enriquez Vera
Citation Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373
Authors D. Enriquez Vera1, G. De la Cruz Ku2, J. Haro Varas3, P. Rioja1, Z. Morante Cruz3, N.I. Valdiviezo Lama1, R. Luque2, E. Eyzaguirre2, M. Lujan2, A. Saavedra2, M. Mayuri Monsefu1, G. Ferreyros1, M. Retamozo Alvarado1, J. Vidal Ayllón1, S. Neciosup Delgado1, L.A. Mas Lopez1
  • 1Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas - INEN, Lima 34 - Lima/PE
  • 2Student, Universidad Cientifica del Sur, 15086 - Lima/PE
  • 3Medical Oncology, INEN, 15 - Lima/PE



ATLL represents a fatal disease epidemiologically linked to chronic infection with human T-cell lymphotropic virus type 1 (HTLV1). The diagnosis is classically described based on morphology, immunophenotype (typically CD7, CD8, CD56, ALK, EBV and PAX5 negatives). Our aim was to describe characteristics and compare outcomes between patients with classical ATLL and those with mature T-cell lymphoma and HTLV1 infection (atypical ATLL).


We reviewed 276 medical records from pts with HTLV1 infection and T-cell lymphomas diagnosed between 2008-2014 at the Instituto Nacional de Enfermedades Neoplasicas (Peru). Groups were divided based on presence of classical characteristics of ATLL, outcomes and survival differences were calculated by log-rank test in the univariate analysis and Cox regression analysis for prognostic factors.


From 276 pts, 126 (45%) had classical ATLL phenotype and 150 (54%) were atypical. Mean age was 56 years and 19% were


It seems that there are atypical presentations of adult T cell lymphoma/leukemia with slightly better response to chemotherapy and survival, further studies with integration of viral RNA to neoplastic tissues are needed to confirm this category.

Clinical trial identification

Legal entity responsible for the study

Instituto Nacional de Enfermedades Neoplasicas




All authors have declared no conflicts of interest.